Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome.

@article{Muchtar2016SystemicIL,
  title={Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome.},
  author={Eli Muchtar and Daniele Derudas and Michelle L. Mauermann and Teerin Liewluck and Angela Dispenzieri and Shaji K Kumar and David Dingli and Martha Q. Lacy and Francis K Buadi and Suzanne R. Hayman and Prashant Kapoor and Nelson Leung and Rajshekhar Chakraborty and Wilson I Gonsalves and Stephen Russell and John A. Lust and Yi Lin and Ronald S Go and Steven R. Zeldenrust and Robert A Kyle and S Vincent Rajkumar and Morie A Gertz},
  journal={Mayo Clinic proceedings},
  year={2016},
  volume={91 10},
  pages={1354-1361}
}
OBJECTIVE To characterize the natural history of immunoglobulin light chain amyloidosis-associated myopathy and to provide guidelines for recognition. PATIENTS AND METHODS Fifty-one patients with systemic immunoglobulin light chain amyloidosis and biopsy-confirmed muscle amyloid deposition diagnosed between January 1, 1995, and December 31, 2015, were included in this study. RESULTS Common presenting symptoms were muscle weakness in 49 patients (96%), dysphagia in 23 (45%), myalgia in 17… CONTINUE READING